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Perforin, a pore-forming protein secreted by cyto-
toxic lymphocytes, is indispensable for destroying
virus-infected cells and for maintaining immune
homeostasis. Perforin polymerizes into transmem-
brane channels that inflict osmotic stress and facili-
tate target cell uptake of proapoptotic granzymes.
Despite this, the mechanism through which perforin
monomers self-associate remains unknown. Our
current study establishes themolecular basis for per-
forin oligomerization and pore assembly. We show
that after calcium-dependent membrane binding,
direct ionic attraction between the opposite faces of
adjacent perforin monomers was necessary for pore
formation. By using mutagenesis, we identified the
opposing charges on residues Arg213 (positive) and
Glu343 (negative) to be critical for intermolecular
interaction. Specifically, disrupting this interaction
had no effect on perforin synthesis, folding, or traf-
ficking in the killer cell, but caused a marked kinetic
defect of oligomerization at the target cellmembrane,
severely disrupting lysis and granzyme B-induced
apoptosis. Our study provides important insights
into perforin’s mechanism of action.
INTRODUCTION
The granule exocytosis pathway is used by cytotoxic lympho-
cytes (CTL or NK cells) to bring about the death of virus-infected
or transformed cells (Bolitho et al., 2007). After the formation of an
immune synapse, CTL secretory granules polarize to the site of
contact with the target cell, fuse with the CTL cell membrane,
and release their luminal contents into the synapse (Stinchcombe
and Griffiths, 2007; Trapani, 1998). Perforin (PRF) is a crucial684 Immunity 30, 684–695, May 22, 2009 ª2009 Elsevier Inc.effector molecule of CTL and cooperates with proapoptotic
serine proteases (granzymes) to induce cell death. Granzymes
may enter the target cell independently of PRF through fluid-
phase endocytosis after initially binding to the target cell
membrane electrostatically (Bird et al., 2005; Trapani et al.,
2003). However, the pore-forming activity of PRF is critical for
the regulated access of granzymes to the cytosol, where they
cleave key substrates to initiate apoptotic death (Froelich et al.,
1996; Nakajima et al., 1995; Shi et al., 1997). PRF is essential
for all granule-mediated cytotoxicity, as has been extensively
demonstrated in gene-targeted PRF-deficient mice (Kagi et al.,
1994) and in humans, where congenital PRF deficiency results
in the potentially fatal immunoregulatory disorder, type 2 familial
haemophagocytic lymphohistiocytosis (FHL) (Stepp et al., 1999;
Voskoboinik et al., 2006). Incomplete loss of PRF function has
also been linked to hematological cancer (Clementi et al., 2005;
Mehta et al., 2006; Voskoboinik et al., 2007), although the findings
remain controversial and a feasible mechanism to explain the
association is still lacking. In other experimental scenarios, PRF
appears to be a critical mediator of tissue damage, for instance
the auto-immune beta cell destruction that results in juvenile-
onset (type 1) diabetes in nonobese diabetic mice (Kagi et al.,
1997).
Despite its function in regulating immune homeostasis and its
critical role in viral immunity, PRF’s molecular function remains
poorly understood, and predictions on the functional significance
of certain of its subdomains have never been experimentally
tested. For more than two decades, PRF has been known to share
sequence and antigenic similarity with lytic proteins of the
complement membrane attack complex (MAC) (Tschopp et al.,
1986; Young et al., 1986a). The electron microscopic appear-
ances of PRF and MAC pores were also shown to be quite similar
(Blumenthal et al., 1984; Dennert and Podack, 1983; Masson
and Tschopp, 1985; Podack and Dennert, 1983; Young et al.,
1986a). The major area of sequence similarity between PRF
and MAC proteins was aptly named the membrane attack
complex-perforin (MACPF) domain, reflecting the fact that no
other known proteins possessed such a domain (Kwon et al.,
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Pore Formation by Lymphocyte Perforin1989; Lichtenheld et al., 1988; Shinkai et al., 1988). Soon after
this, the members of this protein family were proposed to insert
into the target cell membrane via two closely adjacent amphi-
pathic a-helical motifs in the MACPF region, and this view of
pore formation has remained dogma ever since (Peitsch et al.,
1990; Shinkai et al., 1988).
Despite the suggested importance of the proposed amphi-
pathic a helices, a lack of suitable methodologies for expressing
and purifying PRF and indeed other MACPF family members has
meant that direct testing of their function during pore formation
has not been feasible. However, we have now developed robust
and validated expression systems for purifying recombinant PRF
and also for examining its function in the context of an intact CTL
(Voskoboinik et al., 2004, 2005a, 2005b), enabling us to revisit this
issue. It has also become apparent of late that the MACPF
domain is far more widely distributed in nature than previously
suspected, with evolutionary conservation of the MACPF fold
extending back as far as the pore-forming toxins of bacteria
(Rosado et al., 2007). Publication of the first two crystal structures
of MACPF proteins human C8a (Hadders et al., 2007; Slade et al.,
2008) and bacterial Plu-MACPF (a putative toxin synthesized
by Photorhabdus luminescens) (Rosado et al., 2007) provided
a considerable advance in our ability to predict structure-function
relationships for PRF (Rosado et al., 2008). The structural data
also revealed that the MACPF domain was much larger than orig-
inally suspected (350 amino acids) and predicted that folding
occurred almost identically to another family of bacterial pore-
forming toxins, the cholesterol-dependent cytolysins (CDCs).
These recent structural findings are also revolutionary because
they reveal that many human pathogens (for instance, Clos-
tridium, Streptococcus, Chlamydia) secrete pore-forming toxins
that fold through a similar molecular mechanism as the very
proteins elaborated by the immune system to eliminate them.
In the present study, we performed a comprehensive functional
analysis to investigate the molecular mechanism of PRF pore
formation. We definitively demonstrated that the highly conserved
amphipathic a-helical region, formerly thought to constitute the
membrane-spanning domain, is involved in a distinct and critical
function, namely the assembly of PRF monomers into a pore
complex. Apart from the more generic calcium-binding C2
domain (Uellner et al., 1997; Voskoboinik et al., 2005a), this study
is, to our knowledge, the first instance in which a molecular
function of PRF has been unequivocally assigned to a specific
subregion of the molecule.
RESULTS
Mutational Analysis of PRF Residues 187–239
Recent advances in our understanding of the structures of
MACPF proteins Plu-MACPF (Rosado et al., 2007), human C8a
(Hadders et al., 2007), and C8a complexed to C8g (Slade et al.,
2008) have clearly indicated that the highly conserved region of
PRF hitherto thought to be an amphipathic a-helical structure
responsible for target membrane insertion must perform a
different function (Peitsch et al., 1990; Persechini et al., 1992).
To resolve this issue, we undertook detailed site-directed muta-
genesis of residues 187–239 of mouse PRF. We made use of
mammalian and baculovirus-based expression modalities that
we had previously established to dissect the functional impactof individual FHL-associated mutations and polymorphisms
(Voskoboinik et al., 2005b) and to map the key residues in the
PRF C2 domain responsible for calcium-dependent membrane
binding (Voskoboinik et al., 2005a), a mandatory step that
precedes membrane insertion and oligomerization.
Our previous studies have shown that only20% of missense
PRF mutations identified in FHL patients specifically affect PRF’s
function at the level of the target cell (and are therefore termed
‘‘postsynaptic’’ mutations), whereas the majority map presynap-
tically; that is, they map to the CTL and produce deleterious
effects on protein folding or trafficking to CTL secretory granules,
resulting in protein degradation (Voskoboinik et al., 2005b). The
current study aimed to understand the basis for PRF’s interac-
tion with the target cell membrane, so our initial step was to
identify those mutations that resulted in postsynaptic defects
of function. We performed an initial screen of 37 missense
mutations at any of 17 charged or polar residues in this region,
by expressing PRF in RBL-2H3 cells (Shiver and Henkart, 1991).
These residues have previously been thought to form the internal
‘‘aqueous’’ surface of the PRF pore.
Three distinct types of outcome were noted with respect to
protein expression and PRF-dependent cytotoxicity (summa-
rized in Table S1 available online and Figure 1A). The smallest
but most interesting group of mutations (n = 6) produced post-
synaptic dysfunctions, but these all occurred at one of only
two of the 17 amino acids tested, residues R213 and D191.
These mutations underwent further characterization and, as
described below, turned out to provide major insights on the
mechanism of PRF polymerization. A second, more common
outcome (n = 14) was presynaptic dysfunction, which we have
previously defined as reduced expression and/or PRF degrada-
tion or truncation in the RBL cells (Voskoboinik et al., 2004). As
was observed previously with FHL-associated mutations (Ishii
et al., 2005; Voskoboinik et al., 2005b), this group of substitutions
invariably led to a marked loss of function (Table S1). Most
commonly, presynaptic dysfunction occurred at residues that
showed extremely high conservation between species as diver-
gent as humans and fish (for instance, residues 189, 220, 221,
231, or 239), presumably because they are critical for protein
folding during its biosynthesis. The third and largest category
of mutations (n = 17) resulted in normal PRF expression and lytic
activity that was equivalent to wild-type (WT)-PRF.
Taken together, our extensive mutational analysis identified
R213 and D191 as crucial residues where mutation significantly
compromised cytotoxic function but had no apparent effect on
protein folding.
A Positive Charge at Residue 213 Is Critical
for Postsynaptic PRF Function
Point mutations affecting residue R213 had variable effects on
PRF function, depending on the nature of the amino acid substi-
tution (Table S1). Retention of a positive charge with the conser-
vative substitution R213K had minimal effects on PRF expression,
processing, and function. Charge reversal (R213E) resulted in WT
protein expression, but dramatically decreased cytotoxicity
(Figures 1B and 1C). By contrast, introduction of an uncharged,
hydrophobic side chain at this position (R213L) resulted in both
decreased cytotoxicity and reduced protein expression (Figures
1B and 1C).Immunity 30, 684–695, May 22, 2009 ª2009 Elsevier Inc. 685
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a charged side chain at position 213 is important for PRF folding
within the effector cell and, additionally, that a positive charge at
this position is critical for its lytic function after exocytosis. We
therefore elected to further investigate R213E-PRF’s reduced
ability to bring about target cell lysis.
The R213E Mutant Is Expressed and Purified as a Stable
Monomeric Protein
To directly demonstrate the postsynaptic nature of the R213E
substitution, WT- and R213E-PRF were purified from cultures
of baculovirus-infected Sf21 cells (Figure S1A). R213E-PRF
was expressed in similar quantity to WT and migrated at the
expected size (67 kDa) on SDS-PAGE. A key prediction for
substitutions such as R213E that cause purely a postsynaptic
dysfunction is that accurate folding of the protein should
preclude the formation of nonspecific higher order complexes
in solution. By using gel filtration chromatography under nonde-
naturing, nonreducing conditions followed by immunoblotting of
the eluted fractions, we confirmed that both WT- and R213E-
PRF (as well as all other mutants studied below) were present
Figure 1. Two Views of the Structure of C8a
(A) The position of residues mutated in this study
(see Table S1) are indicated by spheres and are
numbered with PRF numbering (see Figure S4
for an alignment between PRF and C8a). D191,
R213, and E343 are highlighted in blue (R) and
red (D and E). Mutation of these residues results
in a postsynaptic defect. The G and H helices
are colored pink and are labeled.
(B) Substitution of residue R213 results in a post-
synaptic defect in PRF lysis. Mouse PRF residue
R213 was substituted with a hydrophobic (L) or
charged (K or E) amino acid of similar size, and
the cytotoxicity of PRF-transfected RBL-2H3 cells
against Jurkat target cells was analyzed in a 4 hr
51Cr-release assay at the E:T ratios indicated.
The data points represent the mean ± SD of the
triplicate assay and are representative of at least
three independent experiments.
(C) Immunoblots showing PRF expression in the
RBL-2H3 transfectant cells tested in (B). Actin
staining was used to demonstrate equivalent
protein loading.
(D) The lytic activity of WT- and R213E-PRF. SRBC
(top) and Jurkat (bottom) cell lysis assays were
each performed with equal quantities of WT- and
R213E-PRF at 37C for 20 min in buffer containing
2 mM calcium. Data points represent data pooled
from at least three experiments performed on
different days ± SD.
in solution exclusively as monomers
(Figure S1B). This was in sharp contrast
to recombinant A91V-PRF, a presynaptic
mutation for which we have previously
used the same methodology to demon-
strate spontaneous aggregation (Vosko-
boinik et al., 2007). To further confirm
that R213E-PRF was correctly folded,
we compared its proteolytic degradation
to that of WT-PRF when both proteins were digested with
varying concentrations of trypsin or chymotrypsin. The degrada-
tion patterns of the two proteins were indistinguishable on
SDS-PAGE, confirming that folding of R213E-PRF was equiva-
lent to WT (Figure S1C).
A Role for R213 in PRF Polymerization, but Not Plasma
Membrane Binding
We next compared the ability of recombinant WT- and R213E-
PRF to lyse target cells. To insure that we used closely compa-
rable amounts of the two proteins, each protein batch was
carefully titrated and quantitated by immunoblotting and the
resulting images analyzed by densitometry (Figure S2 and Experi-
mental Procedures). Consistent with the results obtained when
R213E-PRF was delivered by RBL cells (Figures 1B and 1C),
approximatelyfive timesas muchR213E-PRFasWT was required
to achieve equivalent lysis of nucleated (Jurkat) or non-nucleated
target cells (sheep erythrocytes), indicating80% loss of function
(Figure 1D). The difference in lysis was greatly amplified when the
same assay was performed at 22C, in that the mutated PRF was
now unable to achieve 100% lysis (discussed further below).686 Immunity 30, 684–695, May 22, 2009 ª2009 Elsevier Inc.
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Pore Formation by Lymphocyte PerforinFigure 2. Calcium-Dependent Plasma Membrane Binding and Kinetics of WT- and R213E-PRF-Mediated Lysis
(A) Immunoblot analysis showing membrane-bound PRF after equal amounts (150 ng) of WT- and R213E-PRF were incubated with SRBC and various concen-
trations of calcium at 4C. The input lane contains purified PRF alone without the addition of any membranes.
(B) A SRBC lysis assay measuring Hb release in response to equal amounts of WT and R213E-PRF was performed at 37C for 20 min in the presence of 2 mM
calcium or 0.0625 mM calcium. The data are representative of at least three experiments performed on different days.
(C) The kinetics of WT- and R213E-PRF lysis. SRBC lysis assays performed at 37C with equal quantities (400 ng) of WT- and R213E-PRF.
(D) SRBC lysis assays performed at 22C for 20, 40, 60, or 120 min with equal quantities of WT- and R213E-PRF. Data are representative of at least three
experiments ± SD of the triplicate assay.R213E-PRF’s defective lysis could not be put down to a reduction
in target cell membrane binding, because this was shown to be
equivalent across a wide range of calcium concentrations down
to approximately 0.0625 mM. As expected for these authentically
folded proteins, no membrane binding whatsoever was observed
when calcium was used at even lower concentrations or deleted
altogether (Figure 2A). When SRBC lysis was examined by
measuring hemoglobin (Hb) release at the suboptimal concentra-
tion of Ca2+ (0.0625 mM), the loss of function associated with the
R213E substitution was not augmented, further confirming our
finding that defective calcium-dependent lipid binding was not
responsible for loss of function (Figure 2B).
To further investigate R213E-PRF dysfunction, we analyzed
the kinetics of cell lysis. We found that whereas WT-PRF was
able to induce 100% Hb release within 2 min at 37C, complete
lysis by R213E-PRF took 7 min (Figure 2C). The kinetic defect
could be compensated by adding 5 times as much R213E-
PRF to the assay (data not shown). When the assay was repeated
at 22C with various amounts of PRF, maximal Hb release was
achieved with WT-PRF by 20 min. R213E-PRF released far
less Hb over 20 min; however, increasing the incubation time to
120 min resulted in a dose-related but still partial rescue of the
defect (Figure 2D). These results indicated that target cell pore
formation was considerably less efficient for R213E-PRF.To establish the molecular basis for these findings, we used
silver-stained SDS-PAGE to compare the rate of incorporation
of the 67 kDa PRF membrane-bound monomers into SDS-resis-
tant higher-order membrane-inserted PRF oligomers. It has
previously been shown that MAC and ‘‘polyperforin’’ typically
migrate at >1000 kDa under such conditions, suggesting the
incorporation of at least 16 monomers into the complexes
(Podack and Tschopp, 1982; Young et al., 1986b). Lysis of
SRBC at 37C resulted in the progressive appearance of the
polyperforin signal, which was clearly detectable by 2 min. This
was accompanied by a corresponding loss of the signal for the
PRF monomer (Figure 3A). By contrast, the rate of incorporation
of monomeric R213E-PRF into polyperforin was slowed (for
example, compare the relative signals at 2 min), and some
residual monomer was still present at the later time points
(10 and 20 min; Figure 3A). Immunoblot analysis confirmed that
after 20 min at 37C, more of the R213E-PRF remained in its
membrane-bound monomeric form than WT-PRF, consistent
with less having been incorporated into polyperforin (Figure 3B).
As PRF monomers associate into pore-like structures through
noncovalent bonding, we reasoned that it should be possible to
recover the signal for monomeric PRF by applying suitable dena-
turing conditions to membrane-inserted polymerized PRF. When
the lysed erythrocyte ‘‘ghosts’’ were dissolved and boiled in SDSImmunity 30, 684–695, May 22, 2009 ª2009 Elsevier Inc. 687
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monomeric WT- and R213E-PRF were equalized (Figure 3B).
Once again, this confirmed that a greater proportion of WT- than
R213E-PRF had been incorporated into oligomers and thus
participated in pore formation (Figure 3B). By using densitometry
to estimate PRF oligomerization over seven similar experiments,
Figure 3. Reduced Incorporation ofMonomeric R213E-PRF into Pol-
yperforin, Compared with WT-PRF
(A) Equal amounts of WT- and R213E-PRF (1 mg) were incubated with SRBC at
4C or 37C for up to 20 min and both the membrane-inserted polymeric PRF
(1000 kDa) and monomeric membrane-bound PRF (65 kDa) were visualized
by silver-stained SDS-PAGE. The input lane contains purified PRF alone
without the addition of SRBC. The data are representative of experiments per-
formed a minimum of three times on different days.
(B) Immunoblot analysis comparing membrane-bound monomeric PRF
(65 kDa) after equal amounts of WT- and R213E-PRF (150 ng) were incubated
with SRBC at 4C or 37C for up to 20 min. The data are representative of
western blot experiments performed seven times on different days.
(C) Immunoblots from seven similar experiments were scanned and densitom-
etry was used to compare the levels of membrane-bound R213E- and WT-PRF
remaining unincorporated into polyperforin after incubation at 37C. The signal
for membrane-bound PRF at 37C was plotted relative to membrane-bound
PRF at 4C. Data represent the mean ± SD of densitometry measurements
pooled from seven experiments performed on different days.688 Immunity 30, 684–695, May 22, 2009 ª2009 Elsevier Inc.the reduction in oligomer formation by R213E-PRF over a 20 min
incubation with SRBC at 37C was approximately 50%
(Figure 3C, p < 0.01).
Overall, these experiments established that the impaired cyto-
toxic activity of R213E-PRF was not due to reduced membrane
binding, but rather to its inefficient oligomerization and pore
formation.
R213E-PRF Forms Pores of Similar Size to WT
We then went on to investigate whether R213E-formed pores
were distinct from those formed by WT-PRF. PRF pores formed
in vitro and viewed by electron microscopy typically have an
internal diameter of 16 nm and are thought to consist of
16–18 monomers (Young et al., 1986b). Although the lytic defect
of R213E-PRF could be rescued by using a higher concentration
of the mutated protein at 37C, we wished to determine whether
the pores formed by R213E-PRF were of similar or smaller size to
those formed by WT-PRF. One possibility was that the defect
was entirely kinetic, so that R213E-PRF pores were of similar
size to WT but formed at a slower rate, resulting in fewer pores
at early time points. An equally feasible explanation was that
the mutated PRF formed smaller pores than did WT-PRF, but still
of sufficient size to permit the release of Hb or 51Cr from erythro-
cytes or nucleated cells, respectively.
To distinguish these possibilities, three types of experiment
were undertaken. First, the influx of Ca2+ into PRF-treated cells
was examined to determine whether the slowed polymerization
seen with R213E-PRF would result in reduced calcium flux.
Jurkat cells labeled with the ratiometric intracellular calcium
ionophore Indo-1AM were treated with WT- or R213E-PRF at
37C and Ca2+ flux was followed over 15 min via flow cytometry
(Figure 4A; Figure S3). When equal quantities of WT- and
R213E-PRF were added, calcium flux was greater and pro-
ceeded much faster with WT-PRF. When cells were exposed to
a 4-fold molar excess of R213E-PRF, similar calcium influx into
the cells resulted (Figure 4A), again consistent with a lag in poly-
merization for R213E-PRF relative to WT. The second set of
experiments used negative stain electron microscopy to directly
compare the size of pores formed in bilamellar liposomes by WT-
and R213E-PRF. This highly sensitive technology also enabled us
to confirm visually that both WT- and R213E-PRF remained
exclusively in the monomeric state unless both lipid vesicles
and calcium were also present (data not shown). We confirmed
that there was no difference in the size or shape of WT- or
R213E-PRF pores when amounts of PRF resulting in equivalent
lysis were used (Figure 4B). Both formed cylindrical pores of
14–22 nm diameter, although pore formation at 37C required
3–5 times longer incubation times for R312E-PRF compared
with WT-PRF. A pore diameter of 14–22 nm is consistent with
the pore sizes determined for native PRF during the 1980s
(Podack et al., 1985; Young et al., 1986b). Finally, the ability of
R213E-PRF to facilitate granzyme-B (GrzB)-dependent target
cell apoptosis was determined in comparison with WT-PRF by
measuring the appearance of Annexin V/PI double-positive
Jurkat cells (Figure 4C; Figure S4A) or 51Cr release (Figure S4B)
upon exposure to PRF and GrzB. When equimolar quantities of
R213E- and WT-PRF were used, the capacity of GrzB to induce
apoptosis was severely compromised in cells treated with
R213E-PRF (Figure 4C; Figure S4B). However, when the weaker
Immunity
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Pores
(A) Indo-1AM-labeled Jurkat cells were exposed to equal concentrations of
WT- and R213E-PRF, or concentrations resulting in equal cell lysis (35%) for
20 min at 37C in buffer containing 1 mM calcium. Calcium flux was deter-
mined by the ratio of violet:blue wavelengths over time, via flow cytometry.
Only viable (PI-negative) cells were analyzed. A software program designed
by V. Gromov (IT Department, Peter MacCallum Cancer Centre) allowed an
average readout of 10 data points to be plotted per unit time. This represented
an average of 60–70,000 cells at a flow rate of 80–120 cells/s. A trendline waslytic activity of R213E-PRF was compensated by using 5-fold
more mutant protein, there was no difference in the number of
cells killed through GrzB-dependent apoptosis (Figure 4C;
Figure S4B). This result was further reflected by the percentage
of viable cells remaining 24 hr after PRF/GrzB treatment
(Figure S4A).
Thus, our results across three very different types of assay
consistently indicated that R213E-PRF produces pores of similar
size to WT, confirming that the defect in R213E-PRF function
was principally kinetic in nature.
PRF Oligomerization Involves Protein-Protein
Interactions between the Flat Faces of the Molecule
The crystal structure of the MACPF domains of C8a and Plu-
MACPF revealed that the MACPF domain adopts an unusual flat-
tened cuboid-like shape (Hadders et al., 2007; Rosado et al.,
2007). By analogy with CDCs, it is proposed that PRF oligmerizes
through protein-protein interactions made between the two
largest flat faces of the MACPF domain (Figure S5). Consistent
with a role in oligomerization, our data reveal that R213 maps to
one of two a helices (the H helix) (Rosado et al., 2007) that we
predict would be buried in the interface of a PRF oligomer
(Figure 1A; Figure S5). We therefore postulated that residues in
the other helix (the G helix) may perform a similar function. Exam-
ination of the structures of both C8a and Plu-MACPF suggested
that PRF residue D191 on the G helix would be surface exposed
(Figure 1A; Figure S5). We therefore made mutations at this posi-
tion to test the idea that residues on both the G and H helices are
important in oligomerization. Consistent with our prediction, and
also with the finding that mutations introduced at residue D191
produced postsynaptic defects (Table S1), we found that
substitutions at D191 (D191V, D191K, and D191S) all exhibited
WT expression but markedly decreased cytotoxicity (Figures
5A and 5B). Charge reversal (D191K) or substitution with a hydro-
phobic residue (D191V) resulted in a more dramatic phenotype
than did substitution with a polar noncharged side chain (D191S).
The D191K substitution resulted in a complete loss of cytotox-
icity and some residual lysis could be demonstrated for D191V,
so baculovirus-expressed D191V-PRF was purified to examine
its capacity for lysis and polymerization. Similar to the R213E
substitution, D191V-PRF exhibited a reduction in lytic activity
of 75%, which became more pronounced when the assay
was performed at 22C (Figure 5C). Once again, a defect in
polymerization was noted, in that less of the D191V monomer
became incorporated into polyperforin (Figure 5D).
Together, these data indicated the importance of an acidic
residue at position 191, functioning cooperatively in PRF oligo-
merization with a basic side chain at position 213.
drawn as an approximation of calcium flux. The data are representative of
experiments performed a minimum of three times on different days.
(B) Representative negative stain electron microscopy images of pores formed
by recombinant WT- or R213E-PRF in bilamellar liposomes. Both PRFs formed
pores of similar shape and size, with diameters ranging from 14 to 22 nm.
(C) Apoptosis induced by purified gzmB and PRF. The proapoptotic effect of
human gzmB (25–50 nM) was assessed in synergy with equal concentrations
of WT- or R213E-PRF, or with PRF concentrations adjusted to produce equal
levels of cell lysis when used alone. Apoptotic Jurkat cells were enumerated by
flow cytometry measuring Annexin+PI double-positive cells. Data are repre-
sentative of at least three experiments performed on different days.Immunity 30, 684–695, May 22, 2009 ª2009 Elsevier Inc. 689
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Pore Formation by Lymphocyte PerforinFigure 5. The Effect of Amino Acid Substitutions at Residue D191 on Mouse PRF Function
(A) D191 was substituted with hydrophobic (V), charged (K), or polar (S) amino acids of similar size, and the cytotoxicity of PRF-transfected RBL-2H3 cells against
Jurkat target cells was analyzed in a 4 hr 51Cr-release assay at the E:T ratios indicated. The data shown are the mean ± SD of the triplicate assay and are repre-
sentative of at least three independent experiments.
(B) Western blotting showing the levels of PRF expression in transfected RBL-2H3 cells. Actin staining was used to demonstrate equivalent protein loading.
(C) Measured Hb release after equal quantities of WT- and D191V-PRF were incubated with SRBC at 37C (top) and 22C (bottom) for 20 min in buffer containing
2 mM calcium. Data are representative of at least three experiments performed on different days ± SD of the triplicate assay.
(D) Western blot analysis showing a marked increase of membrane-bound D191V-PRF remaining in the monomeric form (65 kDa) compared to WT-PRF, after
equal amounts were incubated with SRBC at 4C or 37C for up to 20 min. The data are representative of experiments performed a minimum of four times on
different days.R213 and E343 on Adjacent Monomers Form a Salt
Bridge during PRF Polymerization
Our data revealed that R213 and D191 are both important for
PRF oligomerization and pore formation and that disturbances
of charge at these positions resulted in a marked loss of function.
Structural analyses suggested that both residues map to one of
the large flat faces of the PRF MACPF domain (Figure 1A;
Figure S5). To build on this discovery, we decided to investigate
whether residues on the opposite flat face of the PRF MACPF
domain perform an analogous role. Sequence mapping revealed
that the acidic residue E343 was located in the center of the
opposite flat face and thus may contribute to oligomerization
(Figure 1A; Figure S5). Because E343 is located in a conserved
region with no insertions or deletions and is adjacent to a highly
conserved proline residue (Figure S5), we were able to map the
position of this residue with confidence. Further, our molecular
modeling of a PRF oligomer suggested that this residue might
be appropriately placed to interact with R213 by means of
a salt bridge (Figure 6; Figure S5).
To test these ideas, we expressed and tested the function
of E343R-PRF in RBL-2H3 cells. We found that like R213E-,690 Immunity 30, 684–695, May 22, 2009 ª2009 Elsevier Inc.E343R-PRF exhibited WT expression, but had markedly
decreased cytotoxicity (Figures S6A and S6B). Recombinant
E343R-PRF was next purified from baculovirus-infected cul-
tures. Like R213E, purified E343R-PRF remained a monomer in
solution (see Figure S1B). Consistent with the idea that E343 is
important for oligomerization and function, we noted a substan-
tial loss of lytic function for E343R-PRF, which became far more
pronounced at 22C (Figures 7A and 7B). Furthermore, a defect
in polymerization similar to that of R213E-PRF was also seen, in
that incorporation of E343E-PRF monomer into polyperforin was
slowed, as shown by immunoblot (Figure 7C). These data sug-
gested that residue E343 plays an analogous role to D191 and
R213 in PRF oligomerization. Given the clear phenocopying
observed with R213E- and E343R-PRFs, it was not surprising
that R213E-PRF showed a similar substantial reduction in func-
tion when the lysis reaction was carried out at 22C (Figures 7A
and 7B). This result could not be put down to unfolding of the
mutant PRF at the lower temperature, as shown by the fact
that shifting the temperature back to 37C after the prior incuba-
tion at 22C caused similar lysis to incubation at 37C alone
(Figure 7D).
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interaction, we incorporated both substitutions into the same
monomer to form the R213E+E343R-PRF double mutant, thereby
introducing a salt bridge ‘‘swap.’’ Remarkably, the double muta-
tion completely rescued both the lytic and polymerization defects
seen at 37C. Even more notably, the double mutation also
completely reversed the more profound loss of function observed
in individual mutants R213E and E343R at 22C (Figures 7A
and 7B). The effect on R213E-PRF function was particularly
profound at reduced temperature (>99% loss of function), as
indicated by the fact that complete lysis was not achieved at
even the highest concentration of PRF.
E343 and R213 map to opposite flat faces of the PRF mono-
mer and thus are unlikely to form intramolecular interactions,
so the data clearly pointed to these two residues forming an
intermolecular salt bridge that is essential for oligomerization
(Figure 6).
DISCUSSION
For more than 20 years, the functional domains of PRF involved in
pore formation have remained unclear, and despite its critical role
in viral immunity and immune homeostasis, PRF’s molecular
function remains the least understood of all the CTL effector
molecules. PRF was first purified in the early 1980s when its
antigenic cross-reactivity with complement component 9, a
membrane-spanning constituent of the MAC, was first appreci-
ated (Tschopp et al., 1986; Young et al., 1986a), and ultrastruc-
tural studies showed that PRF forms barrel-shaped pores with
striking similarity to complement lesions (Blumenthal et al., 1984;
Masson and Tschopp, 1985; Young et al., 1986a). Sequence
alignments revealed significant similarity between PRF and C9
in two adjacent domains, the MACPF domain and an adjacent
EGF-like domain (Kwon et al., 1989; Lichtenheld et al., 1988;
Shinkai et al., 1988). Subsequently, several independent molec-
ular modeling studies predicted this region to contain two
adjacent amphipathic a helices that each inserted into the lipid
bilayer by virtue of its opposing hydrophobic and hydrophilic
surfaces (Peitsch et al., 1990; Persechini et al., 1992; Shinkai
Figure 6. Molecular Model of the Interactions between PRF Mono-
mers
Three PRF monomers are shown. Our data predict that R213 and E343 form
a salt bridge (dashed lines) in the PRF oligomer. A schematic is also shown
in Figure S5.et al., 1988). In the absence of functional or structural data to
the contrary, this model has remained unchallenged ever since.
Typically, helix 1 was suggested to comprise residues 187–203
and helix 2 residues 211–239, connected by a short cytoplasmic
loop (residues 204–210) (Peitsch et al., 1990; Shinkai et al., 1988).
In support of a functional role, this region also contains the highly
conserved MACPF ‘‘signature’’ motif Y/W-G-T/S-H-F/Y-X6-GG.
About half (>30) of all the missense mutations identified in
FHL patients have also been mapped to the conserved signature
motif and the surrounding regions, further emphasizing its func-
tional importance (Molleran Lee et al., 2004; Voskoboinik et al.,
2005b, 2006).
The current study has capitalized on newly developed expres-
sion modalities that enabled us to directly test the long-held
prediction that sequences highly conserved between MACPF
proteins (particularly residues 187–239) are critical for insertion
and spanning of the target cell membrane. After a detailed
mutational and structure-function analysis, we demonstrated
unequivocally that the role of certain residues in this region is
to mediate PRF oligomerization, and we found no evidence of
this region’s involvement in membrane spanning. Our data are
consistent with very recent structure-based predictions that the
membrane-spanning domains of PRF actually comprise the
regions analogous to transmembrane helices 1 and 2 (residues
125–140 and 255–270) in MACPF proteins and CDCs (Rosado
et al., 2007; Rossjohn et al., 1997), which unfold into b strands
and ultimately form a b-barrel pore.
Of 17 polar or charged residues that were mutated, two key
residues (D191 and R213) were found to be directly involved
in polymerization, in that several amino acid substitutions at
those positions had no substantial effect on PRF processing or
trafficking within the effector cell, but nonetheless resulted in
a marked reduction in target cell lysis, thus representing post-
synaptic defects. Overall, the data provide incontrovertible func-
tional evidence against the long-held view that most conserved
residues of PRF and MACPF proteins in general play a critical
role in membrane insertion. Our major observations were
centered on a substitution (R213E) that introduced a charge
reversal at this position. This change in charge was mapped to
one of the side chains protruding from the H helix in the PRF
MACPF domain. Consistent with the reduced function seen
when R213E-PRF was tested in a cell-based assay, purified re-
combinant R213E-PRF also had decreased lytic function
compared with WT-PRF, resulting from slowed polymerization
and pore formation. Importantly, multiple assays including the
direct visualization of the pore by negative stain electron micros-
copy clearly demonstrated that R213E-PRF formed pores of
similar size to those formed by WT-PRF or described in EM
studies that used PRF purified from primary CTLs (Blumenthal
et al., 1984; Masson and Tschopp, 1985; Young et al., 1986a).
Our results for residue R213 were validated by investigations
on a second amino acid D191, which maps to the adjacent G
helix. Our data revealed that D191V-PRF almost exactly phe-
nocopied R213E-PRF. Insight into the exquisite specificity of
intermolecular PRF interactions can also be gleaned by analysis
of mutations that have a modest or no effect on lytic activity.
Analysis of other charged residues such as K194 and R197 via
the structure of C8a suggest that, like D191, both of these resi-
dues are located on helix G. However, as a result of the helicalImmunity 30, 684–695, May 22, 2009 ª2009 Elsevier Inc. 691
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Pore Formation by Lymphocyte PerforinFigure 7. The Lytic Activity of WT-, R213E-, E343R-, or R213E+E343R-PRF
(A and B) Hb released from SRBC after incubation with equal quantities of WT-, R213E-, E343R-, and R213E/E343R-PRF at 37C (A) or 22C (B) for 20 min in
buffer containing 2 mM calcium. The data are representative of at least three experiments performed on different days ± SD of the triplicate assay.
(C) Immunoblot comparing the recovery of membrane-bound PRF monomers (65 kDa) after equal amounts of WT-, E343R-, and R213E/E343R-PRF were incu-
bated with SRBC at 4C or 37C for up to 20 min. Data are representative of experiments performed a minimum of four times on different days.
(D) The activity of R213E-PRF was restored to its maximal level relative to WT-PRF when a 22C reaction similar to that shown in (B) was followed by a further
20 min incubation at 37C.rotation, we predict that the side chains of both K194 and R197
are positioned such that they point away from the plane of the
proposed oligomerization interface.
Sequence mapping and molecular modeling with the recently
published crystal structures of human C8a and the bacterial
protein Plu-MACPF reveal that both R213 and D191 map to
one of the two ‘‘flat faces’’ of the MACPF domain (Hadders
et al., 2007; Rosado et al., 2007). Cryo-EM studies (Tilley et al.,
2005) of the homologous CDC family reveal that the correspond-
ing region in CDCs is buried in the oligomeric pore form of these
proteins. Together, these data suggest a consistent structural
explanation for the observation that R213 and D191 are important
for oligomerization. Based upon these data, we postulated that
ionic interactions on the opposite face of the PRF MACPF domain
would also be important for oligomerization. Accordingly, we
hypothesized that the residue E343 might be involved in PRF olig-
omerization. Indeed, the E343R mutation resulted in substantially
reduced lytic activity, likewise attributable to a polymerization
defect. Given the opposite charge of R213 and E343, we further692 Immunity 30, 684–695, May 22, 2009 ª2009 Elsevier Inc.predicted that these residues might be ‘‘docking’’ partners
through a salt bridge. In strong support of this hypothesis, when
we ‘‘swapped’’ the amino acid charges and generated the
E343R+R213E double mutation, the lytic and polymerization
phenotypes were restored completely to WT.
Our data provide detailed mechanistic understanding of PRF
pore assembly. Taken together with the structural and mecha-
nistic information available for CDCs, our data also provide
a broader insight into pore formation by lytic MACPF proteins.
This model suggests that these molecules assemble into pores
via a common mechanism; namely oligomerization via the large
flat faces of the MACPF domain. However, it is interesting to note
that none of the positions identified in this study as being impor-
tant for oligomerization (i.e., D191, R213, and E343) correspond
to highly conserved positions in either the MACPF superfamily or
a subset of lytic membrane-inserting MACPF proteins such as
C9 or C8a (Figure S5; Rosado et al., 2007). Thus we suggest
that residues on the flat ‘‘oligomeric’’ faces of different subfam-
ilies of lytic MACPF proteins may have evolved for the particular
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is essential that oligomerization and pore formation of PRF is
prevented prior to its exocytic release from CTL granules. Our
mutational analysis of PRF reveals that both acidic and basic
residues are important for pore assembly. Because the pH of
the lysosome-like granules is low (4.9), key acidic residues
such as D191 and E343 are predicted to be protonated where
PRF is granule bound, so that a durable ionic interaction with
other monomers is unlikely. We have previously shown that
a similar mechanism is responsible for preventing premature
activation of PRF within the CTL granule, because the proton-
ation of aspartate residues within the C2 domain prevents
calcium binding within the acid granule milieu (Voskoboinik
et al., 2005a). Therefore, a single mechanism that regulates
PRF’s intra- and intermolecular ionic interactions appears to
be responsible for at least two key controls on premature PRF
activation.
In summary, the current study has assigned a unique function
(oligomerization) to a region of PRF long thought to perform an
alterative critical function, membrane insertion. Rather, the
recently available structural data clearly suggest that the trans-
membrane region instead consists of helices 1 and 2 (TMH1
and TMH2). The crystal structures of C8a and Plu-MACPF have
also revealed their protein fold to be similar to those of the
b-pore-forming toxin family, the CDCs. The CDCs do not possess
alpha helices capable of membrane spanning, but instead
are thought to form a ‘‘pre-pore’’ prior to insertion, to enable
membrane-interacting domains to be revealed (Dang et al.,
2005; Tilley et al., 2005). This mechanism of pore formation
sees polymerization occurring after membrane binding and
prior to membrane insertion. Such a finding challenges current
perceptions regarding PRF function, in that it has always been
assumed that oligomerization would come after the insertion of
PRF monomers. Based on the high degree of structural similarity
predicted between PRF and these b-PFT, further studies are
warranted to determine whether PRF inserts into membranes
via such a CDC-like mechanism.
EXPERIMENTAL PROCEDURES
Cell Culture, Transfection, and Immunoblotting
Rat basophil leukemia (RBL-2H3, referred to as RBL) cells were cultured,
transfected, and used in cytotoxicity assays as described (Voskoboinik
et al., 2005b). To eliminate potential differences in transfection efficiency, tran-
sient transfections of the effector RBL cells were performed with a pIRES-GFP
vector, and GFP-positive transfectants were sorted 20–24 hr later on the basis
of identical GFP fluorescence (Sutton et al., 2008; Voskoboinik et al., 2005b).
Although IRES-driven GFP fluorescence was used as a surrogate marker for
PRF expression in this initial cell sort, all cell populations used in cytotoxicity
experiments were also tested directly for PRF expression by western blot,
with the rat anti-mouse PRF monoclonal antibody P1-8 (for example, as shown
in Figures 1B and 1C). Mouse anti-human actin monoclonal antibody was used
as an independent control for protein loading (ICN Biomedicals). To generate
missense mutations, site-directed mutagenesis of the mouse PRF cDNA was
performed with the QuickChange methodology (Stratagene).
Purification and Characterization of Recombinant PRF
Recombinant PRF was purified from the supernatants of baculovirus-infected
Sf21 cells, as described (Sutton et al., 2008). All batches of mutant PRF
(R213E, D191V, E343R, and R213E/E343R) were expressed, purified, and
stored in parallel with simultaneously expressed WT-PRF, and functional
assays were carried out within 2–3 days. To ensure that similar amounts ofWT and mutant PRFs were used in functional assays, various volumes of the
protein stocks were sampled and probed by immunoblotting with P1-8. Densi-
tometry on the resultant images was used to construct a standard curve for
each batch of protein (Figure S2). Spontaneous protein aggregation in the
preparations of purified PRF was excluded by performing gel filtration, fol-
lowed by western blotting of the eluted fractions. Gel filtration was carried
out under nondenaturing, nonreducing conditions, as follows. A Superdex
200 HPLC column (GE Healthcare) was equilibrated with PRF storage buffer
(aqueous buffered salt solution) and successive fractions of equal volume
were eluted with the same buffer (Figure S1B). The column was calibrated
by running Mr standards of known mass with the same buffers and under
the same conditions (Voskoboinik et al., 2007).
Trypsin- and Chymotrypsin-Mediated Cleavage of PRF
Trypsin and chymotrypsin were serially diluted (25–6.25 mg/ml) in PRF elution
buffer (10 ml). Purified PRF (3 mg) was added, the reaction volume was adjusted
to 20 ml, and the samples were incubated at 37C for 20 min. Protein sample
buffer (23) was added, and samples were analyzed by SDS-PAGE stained
with 0.25% w/v Coomassie blue.
SRBC Lysis
Sheep red blood cells (SRBC, Centre for Animal Biotechnology, University of
Melbourne) were extensively washed in (20 mM [pH 7.4]) buffered saline solu-
tion (HE) to remove plasma proteins prior to use. SRBC lysis was determined by
estimating haemoglobin release into the supernatant (absorbance at 405 nm).
Controls included SRBC resuspended in water (total release) or HE (sponta-
neous release).
Lysis and Apoptosis of Jurkat Cells
Jurkat cell lysis and apoptosis was analyzed by measuring annexin+PI-posi-
tive cells via flow cytometry and specific 51Cr release as described elsewhere
(Sutton et al., 2008).
Binding of Recombinant PRF to Plasma Membranes
This assay was modified from a method described by us (Voskoboinik et al.,
2005a). All stages of the assay were at 4C, and cells were washed with ice-
cold buffers. Recombinant PRF was incubated with SRBC (2 3 107) and
CaCl2 in a final volume of 200 ml HE for 5 min. SRBC were pelleted by centrifu-
gation, resuspended in the same buffer, and repelleted. The cells were then
lysed with DDW, subjected to SDS-PAGE, and transferred to nylon membranes
for immunoblotting.
PRF Polymerization
PRF (150 ng) was incubated with SRBC (2 3 107) for 5 min in HE containing
2 mM CaCl2 at 4
C, pelleted by centrifugation at 4C, washed in the same
ice-cold buffer, and resuspended in 50 ml of the same buffer at 37C for varying
times. The cells were immediately chilled on ice, pelleted once again at 4C,
resuspended in SDS sample buffer or SDS sample buffer containing 8 M
urea, subjected to SDS-PAGE, and transferred to nylon membranes for immu-
noblotting. Silver-stained gels were run on step SDS-PAGE with the stack
section at 4% (w/v), the top separating section at 6% (w/v), and the bottom
separating section at 10% acrylamide.
Calcium Flux
Jurkat cells were labeled with 2 mM Indo-1AM (Invitrogen), an emission-ratio-
metric fluorescence indicator for quantifying intracellular Ca2+, in HE buffer
for 20 min at 37C and washed three times. 1 3 105 labeled Jurkat cells
were resuspended in HE/1 mM CaCl2 containing 0.5 mg/ml 7AAD. The ratio
of absorbance at 420:510 nm was estimated to obtain a baseline reading prior
to PRF addition.
Structural Analysis
Structural analysis of PRF was performed with the structures of C8a and
Plu-MACPF. Superpositions of C8a and Plu-MACPF were performed with
MUSTANG (Konagurthu et al., 2006). Alignments were produced with clustalW
(Larkin et al., 2007) and manually edited to take secondary structure into
account. All figures were produced with PYMOL (DeLano Scientific LLC).Immunity 30, 684–695, May 22, 2009 ª2009 Elsevier Inc. 693
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structure of human C8a (2QQH, 2RD7) as a template in the program MODELER
(Eswar et al., 2008) as deployed in Quanta (Accelrys inc) and via modeling/
refinement techniques as described (Myers et al., 2000; Whisstock et al.,
1996). The alignment between murine PRF and human C8awas used as a basis
for building the model (Figure S3). Residues that were disordered in electron
density in the template C8a or that represent significant insertions C8a with
respect to PRF were not modeled (residues 81–83, 131–139). A schematic of
a PRF trimer (Figure 6) was generated by manually positioning PRF monomers
with respect to one another so that no steric clashes were apparent.
Negative Stain Electron Microscopy of PRF Pores in Liposomes
Liposomes were prepared by extrusion (via Mini-Extruder, Avanti Polar Lipids,
Alabaster, USA) from a 1:1 molar ratio of cholesterol and phosphatidylcholine
(MacDonald et al., 1991). Monomeric PRF was added to fresh liposomes (final
lipid concentration of 2 mM) at a molar ratio of 1:40007000 total lipids in
the following buffer: 0.15 M NaCl, 1 mM CaCl2, 20 mM HEPES (pH 8.0). The
mixture was placed on ice for 1–2 min and then incubated at 37C for 1–3 min
for WT-PRF and 5–10 min for R213E-PRF. Immediately after this, the sample
was applied to a freshly glow-discharged carbon-coated copper grid and nega-
tively stained with a few drops of 1% w/v uranyl acetate. Micrographs were
collected under low-dose conditions on a Tecnai T12 electron microscope (FEI,
Eindhoven, The Netherlands) operating at an accelerating voltage of 120 keV.
Images were taken at 52,0003magnification (defocus range 0.7–0.9 mm).
SUPPLEMENTAL DATA
Supplemental Data include six figures and one table and can be found with this
article online at http://www.cell.com/immunity/supplemental/S1074-7613(09)
00189-7.
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